1. Pink Sheet
  2. >>Pathways & Standards

To Save Pepaxto, Oncopeptides Throws Shade At IMiD Use In Elderly Myeloma Patients

 
• By Sue Sutter

Seeking to head off US FDA withdrawal of its alkylating agent, sponsor says pomalidomide comparator in OCEAN confirmatory trial rendered overall survival results difficult to interpret because immunomodulatory drugs are detrimental in elderly patients. CDER says IMiD analysis is exploratory and cannot negate adverse overall survival finding with Pepaxto.

Chain link
Oncopeptides says its withdrawal appeal brief for Pepaxto describes the 'missing link' for why elderly myeloma patients have not seen improved survival. • Source: Shutterstock

Oncopeptides AB’s argument against US Food and Drug Administration withdrawal of its akylating agent Pepaxto (melphalan flufenamide, or melflufen) rests upon what it says are the shortfalls in efficacy and safety with another class of drugs used to treat elderly multiple myeloma patients.

Key Takeaways

  • Oncopeptides says Pepaxto’s accelerated approval should not be withdrawn because the OCEAN overall survival results were complicated by use of pomalidomide, an immunomodulatory drug, as a comparator

In its written

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.